Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02030067
Other study ID # RX-3117-P1-01
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date December 2013
Est. completion date December 2019

Study information

Verified date November 2023
Source Processa Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced bladder cancer).


Description:

This is a dose-finding, open-label, single agent study of RX-3117. Once the maximum tolerated dose is identified additional subjects will be treated in a dose expansion followed by a 2-stage Phase 2 study. Subjects will be treated for up to 8 cycles of therapy. A cycle will be 4 weeks. RX-3117 dosing will be 3 times each week for 3 weeks follow by 1 week off treatment. All subjects will be followed for at least 30 days after the last dose of RX-3117.


Recruitment information / eligibility

Status Completed
Enrollment 127
Est. completion date December 2019
Est. primary completion date July 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Males or females who are 18 years or older - Able to swallow capsules - Histological or cytological evidence of confirmed metastatic pancreatic or advanced bladder cancer - Able to discontinue all anticancer therapies 2 weeks prior to study start - Measurable or evaluable disease using Response Evaluation Criteria in Solid Tumors - Life expectancy of at least 3 months - ECOG performance status of 0 or 1 - Provide written informed consent Exclusion Criteria: - Primary brain tumors or clinical evidence of active brain metastasis - Systemic corticosteroid use within 7 days before planned start of study therapy - Active infection requiring parenteral or oral antibiotics within 2 weeks before planned start of study therapy - Uncontrolled diabetes as assessed by the investigator - Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus - History of bone marrow of solid organ transplantation - History of congestive heart failure, arrhythmias, acute coronary syndrome or torsades de pointes - Any other medical, psychiatric, or social condition, which in the opinion of the investigator, would preclude participation in the study, pose an undue medical hazard, interfere with the conduct of the study, or interfere with interpretation of the study results - Known hypersensitivity to gemcitabine, azacytidine or cytosine arabinoside - Pregnant, planning a pregnancy or breast feeding during the study - Concurrent participation in another therapeutic clinical trial

Study Design


Intervention

Drug:
RX-3117


Locations

Country Name City State
United States Rexahn Site Birmingham Alabama
United States Rexahn Site Duarte California
United States Rexahn Site Fairfax Virginia
United States Rexahn Site Las Vegas Nevada
United States Rexahn Site Miami Florida
United States Rexahn Site Miami Lakes Florida
United States Rexahn Site New York New York
United States Rexahn Site Saint Louis Missouri
United States Rexahn Site Salt Lake City Utah
United States Rexahn Site San Antonio Texas
United States Rexahn Site Skokie Illinois
United States Rexahn Site Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
Processa Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Biomarker Concentrations in Blood (Phase 1 and Phase 2) Analysis of biomarker data not conducted. Biomarker samples were not analyzed due to previous sponsor terminating clinical program. Baseline and 4, 8, 12, 16 and 32 weeks
Primary Overall Safety Profile Characterized by # of Subjects With Dose-limiting Toxicities (DLTs) in Phase 1 Number of subjects participating in Phase 1 that experienced a DLT during the first cycle of treatment (28 days) 28 days
Primary Overall Safety Profile Characterized by Number of Subjects Experiencing Serious Adverse Events in Phase 1 Number of subjects participating in Phase 1 that experience any SAEs through study completion, up to 224 days (8 cycles of treatment)
Primary Overall Safety Profile Characterized by the Number of Subjects That Discontinue Study Treatment - Phase 1 Number of subjects participating in Phase 1 of study that discontinued study treatment due to a treatment emergent adverse event. through study completion, up to 224 days (8 cycles of treatment)
Primary Overall Safety Profile Characterized by Number of Subjects Experiencing a Treatment Emergent Adverse Event- Phase 1 Number of subjects that experience any treatment-related adverse event. through study completion, up to 224 days (8 cycles of treatment)
Primary Progression Free Survival (Phase 2) Progression Free Survival in Phase 2 of the study for pancreatic and bladder cancer subjects. 4 months
Secondary Area Under the Plasma Concentration Time Curve (AUC) (Phase 1) Pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours after oral administration in Cycle 1 Days 1 and 15
Secondary Best Overall Response Rate (Phase 2) Best Overall Response Rate (includes Complete Response, Partial Response, and Stable Disease) Baseline and at 4, 8, 12, 16 and 32 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2